TechnoVax

What TechnoVax does

TechnoVax Inc. is a privately held, near-clinical-stage biotechnology company headquartered in Elmsford, New York (within the Tarrytown metro area), founded in 2004 by Dr. Jose Galarza — the inventor of the Influenza Virus-Like Particle (VLP) technology while at Wyeth Pharmaceuticals — together with Dr. George Martin, NIH Scientist Emeritus. The company develops vaccines using a proprietary VLP platform produced through a cell-based manufacturing system; VLPs mimic native virus conformation but are non-infectious because they lack viral genetic material, enabling safer and faster vaccine candidates.

TechnoVax's pipeline includes a Universal Flu Vaccine built from remodeled HA proteins that elicit broadly neutralizing antibodies, a Seasonal Tetravalent Influenza VLP vaccine, an Inhaled Powder VLP vaccine co-developed with MannKind Corp. that eliminates cold-chain requirements, a VLP-based RSV vaccine, a Zika vaccine, and a COVID-19 vaccine candidate developed jointly with CUNY Medical School (announced August 2020). The platform originated from a 2006 inbound license of Wyeth's VLP technology and has been extended through in-house R&D supported by NIH grants.

The business model is pre-commercial. TechnoVax has historically been funded through NIH research grants (at least $4.4 million disclosed across multiple awards between 2009 and 2018) and a small contract-research services business offering recombinant proteins, polyclonal antibodies, ELISA services, RSV/dengue reagents, VLP research reagents, and Vero/MDCK cell lines. Planned future revenue is structured around strategic partnerships, licensing arrangements, and royalties with larger pharmaceutical partners — who would carry candidates through advanced clinical development and commercialization — supplemented by the company's bioservices unit. As of the input data, the company has not yet reached commercial revenue.

Name

TechnoVax

Legal name

TechnoVax Inc.

Website

https://technovax.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

TechnoVax is a privately held, near-clinical-stage biotechnology company developing virus-like particle (VLP) vaccines for influenza, RSV, Zika, and COVID-19, funded by NIH grants and contract research services while pursuing pharmaceutical licensing partnerships for commercialization.

Ownership category

akta.pro rank

Product category

Vaccine Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)

Keywords

• Virus-like particle vaccines
• Influenza vaccine development
• Respiratory virus vaccines
• Vaccine contract research
• Recombinant protein services

Headquarters

HQ city

Tarrytown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. NIH Grant Funding: TechnoVax is a privately held near-clinical-stage company currently funded through NIH grants and planned partnership/strategic alliance arrangements. The company has not yet reached commercial revenue stage.
2. Strategic Partnership and Licensing: TechnoVax intends to advance vaccine candidates through strategic alliances, licensing arrangements, and research collaborations. Partners would provide necessary resources to advance candidates through clinical proof of concept, with TechnoVax capturing value through licensing and royalty arrangements.
3. Contract Research Services: Biological Products and Services offered on contractual or collaborative basis for generating high quality reagents and biologicals for research or diagnostic purposes.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

TechnoVax develops Virus-Like Particle (VLP) vaccine candidates for influenza, RSV, COVID-19, and Zika using a proprietary cell-based manufacturing platform licensed from Wyeth. The company also produces and develops novel biologicals (recombinant HA proteins, polyclonal IgG antibodies, ELISA, RSV/Dengue reagents, VLPs, and Vero/MDCK cell lines) on a contract research basis for research and diagnostic use.

Product overview

TechnoVax operates a VLP (Virus-Like Particle) technology platform that serves as the foundation for its vaccine development programs. The platform produces non-infectious VLPs that mimic native viruses without containing genetic material. The core product portfolio includes the Universal Flu Vaccine (using remodeled HA proteins for broadly neutralizing antibodies), Seasonal Tetravalent Influenza VLP Vaccine, Inhaled Powder VLP Vaccines (developed with MannKind Corp. for pulmonary delivery), RSV Vaccine, Zika Vaccine, and COVID-19 Vaccine. These products share the common VLP technology foundation but target different antigens and delivery mechanisms. Additionally, TechnoVax offers a suite of contract biological products and services including recombinant influenza HA proteins, polyclonal IgG antibodies, ELISA services, RSV and Dengue reagents, VLP research reagents, and specialized cell lines (Vero & MDCK) for vaccine research and manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• VLP Technology Platform A next-generation cell-based manufacturing system that produces highly immunogenic, non-infectious monovalent and polyvalent virus-like particle (VLP) vaccines mimicking native virus organization without containing viral genetic material. Licensed from Wyeth and forms the foundation of all TechnoVax vaccine candidates.
• Universal Flu Vaccine VLP-based influenza vaccine assembled with Remodeled HA proteins displaying highly conserved subdominant epitopes that elicit broadly neutralizing antibody responses, providing cross-protection against multiple influenza strains and reducing the need for annual reformulation.
• Seasonal Tetravalent Influenza VLP Vaccine Tetravalent flu VLP vaccine incorporating an additional B antigen beyond WHO recommendations, broadening vaccine protection while reducing manufacturing steps, time, and costs.
• Inhaled Powder VLP Vaccines Shelf-stable, self-inhaled powderized VLP vaccines developed in partnership with MannKind Corp. for flu and RSV; eliminates refrigeration, enables pulmonary mucosal immunization, and supports potential self-administration by patients.
• RSV Vaccine VLP-based Respiratory Syncytial Virus vaccine targeting the leading cause of lower respiratory tract infection in infants, children, and the elderly worldwide.
• Zika Vaccine VLP-based vaccine candidate for Zika virus identified as a gaining-momentum, high-priority pipeline asset.
• COVID-19 Vaccine VLP-based COVID-19 vaccine candidate reported in August 2020 by TechnoVax in collaboration with CUNY Med School; advancing toward clinical Phase I at high speed pending financing.
• Biological Products and Services (Contract Research) Contract and collaborative biological products and services including recombinant influenza HA proteins, polyclonal IgG antibodies, ELISA, RSV reagents, Dengue reagents, VLPs for research, diagnostic, design and modeling applications, and Vero/MDCK cell lines for yield enhancement of virus production. For research and diagnostic use.

Quantifiable outcome

• 64 million RSV infections and 160,000 deaths annually worldwide
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered high, core and supporting.

• CUNY Medical SchoolhighStrategic or Co-development Partner · 1 August 2020TechnoVax and CUNY Medical School reported a COVID-19 vaccine breakthrough in August 2020. The collaboration combined TechnoVax's VLP technology with CUNY's research capabilities to advance COVID-19 vaccine development.
• Wyeth PharmaceuticalscoreTechnology or Integration · 1 December 2006TechnoVax licensed Wyeth's Virus-Like Particle Vaccine Technology in December 2006. This inbound license formed the foundation of TechnoVax's proprietary VLP vaccine platform.
• MannKind Corp.coreStrategic or Co-development PartnerTechnoVax partnered with MannKind Corp., a leading player in pulmonary drug delivery, to develop shelf-stable, self-inhaled powder VLP vaccines for flu and RSV. This collaboration combines TechnoVax's VLP technology with MannKind's inhaled powder delivery technology. Currently there is no such product on the market for respiratory vaccination.
• Centers for Disease Control (CDC)supportingStrategic or Co-development PartnerCDC is listed as part of TechnoVax's strong network of industry, governmental agencies, and academic collaborators.
• New York Medical College (NYMC)supportingStrategic or Co-development PartnerCollaboration with NYMC includes work with Dr. Doris J. Bucher's laboratory, one of only three laboratories worldwide that produce high growth reassortant seed viruses for influenza vaccine. Dr. Galarza serves as adjunct Associate Professor at NYMC.
• City College of New York (CUNY)supportingStrategic or Co-development PartnerCollaborations with CUNY professors Reza Khayat and Paul Gottlieb from The City College of New York supporting vaccine research and development efforts.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• BiondVax Pharmaceuticals: Developed M-001, a universal influenza vaccine candidate based on conserved epitopes. Direct comparable — pursued the same universal flu thesis that is one of TechnoVax's lead programs, illustrating the long and capital-intensive path to licensure in this indication.
• Novavax: Direct VLP-based vaccine developer using recombinant nanoparticle technology. Most direct competitor — pursued COVID-19, influenza, and RSV VLP vaccines through clinical and commercial stages, providing both a comparable technology and a benchmark for VLP commercial viability.
• VBI Vaccines: Clinical-stage biotech using VLP and enveloped VLP (eVLP) platforms for infectious disease vaccines including hepatitis B and COVID-19. Closely comparable in stage, technology (VLP), and indication overlap with TechnoVax's pipeline.
• Medicago (Mitsubishi Tanabe): Developed plant-based VLP vaccines targeting influenza and other infectious diseases. Direct technology parallel — used VLP architectures in similar indications and was acquired by Mitsubishi, illustrating both the strategic value of VLP platforms and the typical exit pathway for a near-clinical-stage player like TechnoVax.

Emerging players

• SpyBiotech: Clinical-stage VLP vaccine developer using its proprietary SpyTag/SpyCatcher technology to decorate VLPs with antigens. Comparable in stage and technology approach (VLP display), and provides a useful benchmark for capital-efficient VLP clinical development.
• iBio: Small clinical-stage biotech with plant-based vaccine and therapeutic platforms. Comparable in size and stage to TechnoVax, with overlapping interest in next-generation vaccine delivery and rapid pandemic response.
• GeoVax Labs: Clinical-stage biotech developing vaccines using viral vector and VLP-style platforms for infectious disease and immuno-oncology. Comparable in scale and stage; relevant for the modified vaccinia Ankara (MVA) vector / VLP adjacency.

Broad incumbents

• Pfizer: Major vaccine manufacturer with approved RSV (Abrysvo) and COVID-19 (Comirnaty) products directly competing with TechnoVax's pipeline. Also represents a credible partner/licensing counterparty given TechnoVax's stated strategy of out-licensing to large pharma.
• GSK (Vaccines division): One of the world's largest vaccine companies, with approved RSV (Arexvy) and seasonal influenza products directly competing with TechnoVax's lead indications. Represents the type of large-pharma partner TechnoVax's business model is designed to attract for late-stage development and commercialization.
• Moderna: mRNA vaccine leader with influenza, RSV, and COVID-19 programs competing head-to-head with TechnoVax's pipeline. Relevant as the dominant alternative vaccine modality whose clinical and commercial success sets the competitive bar TechnoVax's VLP candidates must clear.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/technovax-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TechnoVax